《大行》交银国际升和黄医药(00013.HK)目标价至44元 优异对价出售联营公司权益

阿斯达克财经
08 Jan

和黄医药(00013.HK) 日前宣布,将以6.08亿美元向金浦健服投资管理和上海医药(02607.HK) 出售其在上海和黄药业的45%股权。交银国际认为是次交易条件合理,作价优异,将有助公司进一步聚焦创新研发主业,所得资金预料会用于开发内部产品管线,推动核心业务战略发展,当中包括下一代抗体靶向偶联药物(ATTC)平台,有利于未来长期发展。
因此交银国际将和黄医药的目标价提升至44元,维持“买入”评级,预期公司在中后期管线开发上持续取得关键进展,可成为今年的股价催化剂。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10